Trial Profile

A Randomized, Double Blind, Placebo Controlled, Multi-center, Phase III Study of CD24Fc for Prevention of Acute Graft-Versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efprezimod alfa (Primary) ; Tacrolimus (Primary) ; Tacrolimus (Primary) ; Methotrexate
Indications Graft-versus-host disease
Focus Registrational; Therapeutic Use
Acronyms CATHY
Sponsors OncoImmune

10 Nov 2021 Status changed from active, no longer recruiting to discontinued.
10 Nov 2021 Status changed from active, no longer recruiting to discontinued.
31 May 2021 Planned End Date changed from 18 Feb 2024 to 2 Nov 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com